FRM
TBPH icon

Fox Run Management’s Theravance Biopharma TBPH Stock Holding History

Fox Run Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,964
Closed -$113K – 991
2023
Q2 		$113K Buy
+10,964
New +$121K 0.03% 628

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fox Run Management's TBPH Position: Q3 2023 in Review

Fox Run Management sold out of Theravance Biopharma (TBPH) in Q3 2023, closing a stake of 10,964 shares — an estimated $113K sold.

Fox Run Management first reported a position in TBPH in Q2 2023 and held it in 1 quarter. The position peaked at $113K in Q2 2023. 115 funds tracked by Wall St. Rank hold TBPH as of Q3 2023.

  • Fox Run Management reported no remaining Theravance Biopharma position as of Q3 2023 after selling out during the quarter.
  • Fox Run Management sold 10,964 Theravance Biopharma shares in Q3 2023, an estimated $113K.
  • Fox Run Management first reported a position in Theravance Biopharma in Q2 2023 and held it in 1 quarter.
  • Fox Run Management's Theravance Biopharma position peaked at $113K in Q2 2023.
  • 115 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2023.

Based on Fox Run Management's 13F filing for Q3 2023, filed 7 Nov 2023.